Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. | Blood Adv | 2022 | 35790105 | PubTator, text mining | PubMed |
| Immunoglobulin genes, reproductive isolation and vertebrate speciation. | Immunol Cell Biol | 2022 | 35781330 | PubTator, text mining | PubMed |
| B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. | Blood Cancer J | 2022 | 35778390 | PubTator, text mining | PubMed |
| Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals. | Eur J Haematol | 2022 | 35776688 | PubTator, text mining | PubMed |
| Targeting metabolic reprogramming in chronic lymphocytic leukemia. | Exp Hematol Oncol | 2022 | 35761419 | PubTator, text mining | PubMed |
| Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. | Leukemia | 2022 | 35752657 | PubTator, text mining | PubMed |
| Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. | Eur J Cancer | 2022 | 35752155 | PubTator, text mining | PubMed |
| Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. | Hemasphere | 2022 | 35747845 | PubTator, text mining | PubMed |
| Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. | Cancers (Basel) | 2022 | 35740661 | PubTator, text mining | PubMed |
| Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies. | Biomedicines | 2022 | 35740251 | PubTator, text mining | PubMed |
| Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. | Blood Adv | 2022 | 35736670 | PubTator, text mining | PubMed |
| Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. | Front Oncol | 2022 | 35734588 | PubTator, text mining | PubMed |
| The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. | Leukemia | 2022 | 35732829 | PubTator, text mining | PubMed |
| Coevolved Canonical Loops Conformations of Single-Domain Antibodies: A Tale of Three Pockets Playing Musical Chairs. | Front Immunol | 2022 | 35720356 | PubTator, text mining | PubMed |
| BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. | Nature | 2022 | 35714668 | PubTator, text mining | PubMed |
| Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. | Adv Ther | 2022 | 35708885 | PubTator, text mining | PubMed |
| ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution. | Blood Cancer J | 2022 | 35672297 | PubTator, text mining | PubMed |
| Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. | J Hematol Oncol | 2022 | 35659041 | PubTator, text mining | PubMed |
| Zanubrutinib in lymphoproliferative disorders: a comprehensive review. | Ther Adv Hematol | 2022 | 35651781 | PubTator, text mining | PubMed |
| Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia. | Front Oncol | 2022 | 35646669 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=30